To summarize the pathophysiological mechanisms linking systemic lupus erythematosus (SLE) to accelerated coronary atherosclerosis and explore potential therapeutic interventions, emphasizing the significance for improving patient outcomes.
Key Findings:
SLE patients exhibit a significantly elevated risk of premature coronary atherosclerosis, particularly in young women.
Traditional cardiovascular risk factors do not fully account for the increased risk in SLE patients.
Statin therapy has not effectively normalized atherogenic profiles in SLE, indicating a distinct immunopathological process driven by immune dysregulation.
Dysfunctional HDL and elevated oxidized LDL levels contribute to the pro-inflammatory state in SLE, alongside type I interferon-driven mechanisms.
Interpretation:
The findings suggest that atherosclerosis in SLE is driven by unique immune dysregulation and inflammation, necessitating a shift from traditional lipid-lowering strategies to targeted immunomodulatory therapies.
Limitations:
The review may not encompass all recent studies or emerging therapies.
The complexity of SLE and its varied manifestations may limit generalizability of findings and impact treatment outcomes.
Conclusion:
Understanding the SLE–atherosclerosis nexus is crucial for improving cardiovascular outcomes in SLE patients and developing targeted interventions that address the unique mechanisms involved.
